ReviewTargeted oncology2011
Aging and cancer: can mTOR inhibitors kill two birds with one drug?
Review in Targeted oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adherence to the Mediterranean diet and its protective effects against colorectal cancer: a meta-analysis of 26 studies with 2,217,404 participants.GeroScience · 2025Pooled it
- Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research.GeroScience · 2019Review
- mTOR inhibitors for treatment of low-risk prostate cancer.Medical hypotheses · 2018Article
- Live strong and prosper: the importance of skeletal muscle strength for healthy ageing.Biogerontology · 2016Review
- Article
- Aberrant mTOR activation in senescence and aging: A mitochondrial stress response?Experimental gerontology · 2015Review
- How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story.Experimental gerontology · 2015Review
- Rapamycin increases mitochondrial efficiency by mtDNA-dependent reprogramming of mitochondrial metabolism in Drosophila.Journal of cell science · 2014Article
- Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver.Aging cell · 2014Article
- A cytoprotective perspective on longevity regulation.Trends in cell biology · 2013Review
- Article
- mTOR Inhibition: From Aging to Autism and Beyond.Scientifica · 2013Review
- Should diabetic women with breast cancer have their own intervention studies?Endocrine-related cancer · 2012Article
- Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.Current medicinal chemistry · 2012Review
- Epigenetic regulation of caloric restriction in aging.BMC medicine · 2011Review
- Polyamines in aging and disease.Aging · 2011Review
- Are we ready to move away from nature?: the rapamycin story.Targeted oncology · 2011Article
- Targeting the target of rapamycin (TOR): looking to mother nature.Targeted oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The main risk factor for a number of diseases, including cancer, is aging. By delaying the effects of aging, many years of research indicate that diseases associated with aging are reduced by prolongevity interventions such as reductions in caloric intake and mice genetically deficient for growth factors. Although studies of dietary and growth factor restriction have been highly informative regarding the aging process, they are both unrealistic for human application. Recent preclinical results with a pharmacological prolongevity agent (rapamycin) provide a proof-of-concept that such an approach is feasible in human populations. Exactly how rapamycin works to extend lifespan is under increasingly intense investigation. In addition, these studies underscore the critical role that the intracellular target of rapamycin (TOR) plays in one of the deepest mysteries of life, aging. How age-associated diseases interface with TOR and its signaling systems, and the tremendous opportunities for discovery of new drugs that target both aging and its associated diseases is one of the most exciting areas of research currently being conducted in this new era of aging research.
Indexed as
Identifiers
21394528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.